weight loss with glp-1 agonists Rx Trends: Real-World Data on GLP-1s for Glucagon-like peptide-1 receptor agonists and
Description
& Lund, E
Potential for personalized obesity therapies using AI-driven patient profiling and biomarker analysis
Tirzepatide: a breakthrough therapy for obstructive sleep apnea and metabolic dysfunction
Utility of glucagon-like peptide 1 receptor agonists as anti-obesity medications in liver transplant recipients
GLP-1 receptor agonists were compared to nonuse of GLP-1 receptor agonists in a cohort of 95,490 people (mean age, 50.6 years)
Prior to this several other anti-obesity drugs had also proven disappointing due to adverse effects such as cardiovascular problems, increased suicidal risk and enhanced drug dependence and abuse (Mller, Blher, Tschp, DiMarchi)
